ImmuCell Corporation (ICCC)
ICCC trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$10.79
+12.40% on the day
Market cap
$98.0M
Micro cap
Revenue · 2025
$27.6M
+4.3% on 2024
Net income · 2025
-$1.0M
-3.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ICCC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 1987 |
| SEC CIK | 0000811641 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $27.6M |
| Net income | -$1.0M |
| Operating income | $1.6M |
| Net margin | -3.8% |
| Operating margin | 6.0% |
| Revenue growth | +4.3% |
| Cash | $3.8M |
| Total assets | $42.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B2 | 2024-04-10 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-05-13 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-13 |
| Latest current report FORM 8-K | 8-K | 2026-10-13 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 795 recent filings. All filings on EDGAR.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMDX | Insight Molecular Diagnostics Inc. | $2.99 | -5.68% | $97.8M |
| MYGN | Myriad Genetics Inc. | $4.08 | -2.86% | $390.3M |
| TKNO | Alpha Teknova Inc. | $8.22 | -5.52% | $441.3M |
| NNNN | Anbio Biotechnology | $4.26 | -3.40% | $613.0M |
| ACHV | Achieve Life Sciences Inc. Common Shares | $7.00 | -0.85% | $720.3M |
| QDEL | QuidelOrtho Corporation | $14.10 | +6.42% | $966.9M |
| BMRA | Biomerica Inc. | $1.85 | +0.82% | $8.5M |
| NTLA | Intellia Therapeutics Inc. | $11.91 | -5.33% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier